Ontology representation and analysis of vaccine formulation and administration and their effects on vaccine immune responses

Journal of Biomedical Semantics

Volumn 3, Issue 1, 2012, Pages

  Lin, Yu ^a   He, Yongqun ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887118225     PISSN: None     EISSN: 20411480     Source Type: Journal    
DOI: 10.1186/2041-1480-3-17     Document Type: Article

References (32)

1. He Y, Cowell LG, Diehl AD, Mobley H, Peters B, Ruttenberg A, Scheuermann R, Brinkman RR, Courtot M, Mungall C: VO: Vaccine Ontology. The 1st International Conference on Biomedical Ontology (ICBO 2009). 2009,[http://precedings.nature.com/documents/3552/version/1]
2. Grenon P: Spatio-temporality in Basic Formal Ontology. IFOMIS reports. Edited by: Grenon P. 2003, Leipzig: Institute for Formal Ontology and Medical Information Science at the Faculty of Medicine of the University, 89-
3. Smith B, Ceusters W, Klagges B, Kohler J, Kumar A, Lomax J, Mungall C, Neuhaus F, Rector AL, Rosse C: Relations in biomedical ontologies. Genome Biol. 2005, 6 (5): R46. 10.1186/gb-2005-6-5-r46.
4. de Matos P, Alcantara R, Dekker A, Ennis M, Hastings J, Haug K, Spiteri I, Turner S, Steinbeck C: Chemical Entities of Biological Interest: an update. Nucleic Acids Res. 2010, 38 (Database issue): D249-D254.
5. Brinkman RR, Courtot M, Derom D, Fostel J, He Y, Lord P, Malone J, Parkinson H, Peters B, Rocca-Serra P: Modeling biomedical experimental processes with OBI. Journal of Biomedical Semantics. 2010, 21 (Suppl 21): S27-doi: 10.1186/2041-1480-1181-S1181-S1187.
6. Cowell LG, Smith B: Infectious Disease Ontology. Infectious Disease Informatics. Edited by: Sintchenko V. 2010, New York Dordrecht Heidelberg London: Springer, 373-395.
7. Plotkin SA, Orenstein WA, Offit PA: Vaccines. 2008, Philadelphia, PA: Saunder Elsevier, 5
8. Sayers S, Ulysse G, Xiang Z, He Y: Vaxjo: A Web-Based Vaccine Adjuvant Database and Its Application for Analysis of Vaccine Adjuvants and Their Uses in Vaccine Development. J Biomed Biotechnol. 2012, 2012: 831486-[ http://www.ncbi.nlm.nih.gov/pubmed/22505817 ]
9. Scholl I, Boltz-Nitulescu G, Jensen-Jarolim E: Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J Control Release. 2005, 104 (1): 1-27. 10.1016/j.jconrel.2004.12.020.
10. Liu MA: Immunologic basis of vaccine vectors. Immunity. 2010, 33 (4): 504-515. 10.1016/j.immuni.2010.10.004.
11. Brinkman RR, Courtot M, Derom D, Fostel JM, He Y, Lord P, Malone J, Parkinson H, Peters B, Rocca-Serra P: Modeling biomedical experimental processes with OBI. J Biomed Semantics. 2010, 1 (Suppl 1): S7-10.1186/2041-1480-1-S1-S7.
12. Atkinson W, Wolfe C, Hamborsky J: Epidemiology and prevention of vaccine-preventable diseases. 2011, Atlanta: Dept. of Health & Human Services, Public Health Service, 3-4.
13. Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa AM, Rice-Ficht AC: Brucellosis: the case for live, attenuated vaccines. Vaccine. 2009, 27 (Suppl 4): D40-D43.
14. Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G: Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med. 2005, 11 (8): 853-860. 10.1038/nm1276.
15. van Gelder P, Makoschey B: Production of viral vaccines for veterinary use. Berl Munch Tierarztl Wochenschr. 2012, 125 (3-4): 103-109.
16. Schurig GG, Roop RM, Bagchi T, Boyle S, Buhrman D, Sriranganathan N: Biological properties of RB51; a stable rough strain of Brucella abortus. Vet Microbiol. 1991, 28 (2): 171-188. 10.1016/0378-1135(91)90091-S.
17. de Bagues MP J, Elzer PH, Jones SM, Blasco JM, Enright FM, Schurig GG, Winter AJ: Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis. Infect Immun. 1994, 62 (11): 4990-4996.
18. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB: Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011, 204 (6): 845-853. 10.1093/infdis/jir436.
19. Sanakkayala N, Sokolovska A, Gulani J, Hogenesch H, Sriranganathan N, Boyle SM, Schurig GG, Vemulapalli R: Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51. Clin Diagn Lab Immunol. 2005, 12 (12): 1429-1436.
20. Finn A: Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull. 2004, 70: 1-14. 10.1093/bmb/ldh021.
21. Dintzis RZ: Rational design of conjugate vaccines. Pediatr Res. 1992, 32 (4): 376-385. 10.1203/00006450-199210000-00002.
22. Tamura S, Hasegawa H, Kurata T: Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn J Infect Dis. 2010, 63 (1): 8-15.
23. He Y, Vemulapalli R, Schurig GG: Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu, Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infect Immun. 2002, 70 (5): 2535-2543. 10.1128/IAI.70.5.2535-2543.2002.
24. Schurig GG, Sriranganathan N, Corbel MJ: Brucellosis vaccines: past, present and future. Vet Microbiol. 2002, 90 (1-4): 479-496.
25. Olsen SC, Waters WR, Stoffregen WS: An aerosolized Brucella spp. challenge model for laboratory animals. Zoonoses Public Health. 2007, 54 (8): 281-285. 10.1111/j.1863-2378.2007.01063.x.
26. Surendran N, Sriranganathan N, Lawler H, Boyle SM, Hiltbold EM, Heid B, Zimmerman K, Witonsky SG: Efficacy of vaccination strategies against intranasal challenge with Brucella abortus in BALB/c mice. Vaccine. 2011, 29 (15): 2749-2755. 10.1016/j.vaccine.2011.01.090.
27. Cooper B, DeTora L, Stoddard J: Menveo(R)): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines. 2011, 10 (1): 21-33. 10.1586/erv.10.147.
28. Sarntivijai S, Xiang Z, Shedden KA, Markel H, Omenn GS, Athey BD, He Y: Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. PLoS ONE. 2012, 7 (11): e49941-10.1371/journal.pone.0049941.
29. Smith B, Ashburner M, Rosse C, Bard J, Bug W, Ceusters W, Goldberg LJ, Eilbeck K, Ireland A, Mungall CJ: The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol. 2007, 25 (11): 1251-1255. 10.1038/nbt1346.
30. CDC: Epidemiology and Prevention of Vaccine-Preventable Diseases, The Pink Book: Course Textbook. 2011, Centers for Disease Control and Prevention, [http://www.cdc.gov/vaccines/pubs/pinkbook/index.html]12
31. Xiang Z, Todd T, Ku KP, Kovacic BL, Larson CB, Chen F, Hodges AP, Tian Y, Olenzek EA, Zhao B: VIOLIN: vaccine investigation and online information network. Nucleic Acids Res. 2008, 36 (Database issue): D923-928.
32. Approved Vaccine Products by USA FDA. [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/]